Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 381,440,256
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 17,235 M
  • EBITDA $ 18,602 M
  • 60-Month Beta 0.40
  • Price/Sales 11.32
  • Price/Cash Flow 28.23
  • Price/Book 21.47

Options Overview Details

View History
  • Implied Volatility 33.29% ( +1.97%)
  • Historical Volatility 62.46%
  • IV Percentile 56%
  • IV Rank 27.92%
  • IV High 58.88% on 12/19/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.68
  • Today's Volume 58,911
  • Volume Avg (30-Day) 51,302
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 438,245
  • Open Int (30-Day) 516,707

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.88
  • Number of Estimates 4
  • High Estimate 0.92
  • Low Estimate 0.86
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +23.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.50 +6.80%
on 12/20/24
112.52 -22.64%
on 12/11/24
-18.02 (-17.15%)
since 11/22/24
3-Month
81.50 +6.80%
on 12/20/24
127.61 -31.79%
on 09/25/24
-36.66 (-29.64%)
since 09/23/24
52-Week
81.50 +6.80%
on 12/20/24
148.15 -41.25%
on 06/25/24
-15.67 (-15.26%)
since 12/22/23

Most Recent Stories

More News
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the candidate...

NVO : 87.38 (+2.80%)
MRK : 98.73 (+0.69%)
LLY : 789.21 (+2.79%)
AMGN : 261.21 (-0.82%)
Novo Nordisk Shares Rebound After Friday’s $90B Wipeout: Retail, Analysts See Opportunity

AlphaValue/Baader Europe reportedly argued that Friday’s reaction was “materially overdone,” considering CagriSema’s potential $20 billion peak sales.

NVO : 87.38 (+2.80%)
LLY : 789.21 (+2.79%)
Better Buy: Eli Lilly or Novo Nordisk?

Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.

NVO : 87.38 (+2.80%)
LLY : 789.21 (+2.79%)
Is Merck the Next Big Weight-Loss Stock?

Watch out, Eli Lilly and Novo Nordisk . Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market.

NVO : 87.38 (+2.80%)
MRK : 98.73 (+0.69%)
LLY : 789.21 (+2.79%)
MarketBeat Week in Review – 12/16 - 12/20

Stocks were lower this week after the Federal Reserve confirmed fewer rate cuts in 2025, but Friday's rally suggests hope for a Santa Claus rally remains strong

AVGO : 231.49 (+5.13%)
NVO : 87.38 (+2.80%)
MU : 88.88 (-1.38%)
GS : 569.38 (+0.58%)
SMTC : 62.82 (-1.15%)
DIS : 111.01 (-0.91%)
SEDG : 15.03 (+1.76%)
TSLA : 431.42 (+2.46%)
CAVA : 118.06 (-0.83%)
CMG : 61.44 (-0.70%)
CTAS : 186.11 (-0.44%)
AUR : 6.78 (-5.70%)
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called "Santa Claus rallies" can occur near the end...

NVO : 87.38 (+2.80%)
VRTX : 398.22 (+0.24%)
ABBV : 176.39 (+0.46%)
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.

NVO : 87.38 (+2.80%)
LLY : 789.21 (+2.79%)
Why Viking Therapeutics Tumbled by More Than 10% This Week

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (NASDAQ: VKTX) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence,...

VKTX : 41.47 (-1.85%)
NVO : 87.38 (+2.80%)
MRK : 98.73 (+0.69%)
LLY : 789.21 (+2.79%)
Novo Nordisk Heads For Worst Day In 22 Years As New Obesity Drug Underwhelms: Retail Brushes Off ‘Super Silly’ Drop

On the analyst front, Citi and UBS both described Novo’s readout as favorable for Eli Lilly.

VKTX : 41.47 (-1.85%)
NVO : 87.38 (+2.80%)
LLY : 789.21 (+2.79%)
AMGN : 261.21 (-0.82%)
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.

VKTX : 41.47 (-1.85%)
NVO : 87.38 (+2.80%)
LLY : 789.21 (+2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 92.22
2nd Resistance Point 89.37
1st Resistance Point 87.19
Last Price 87.38
1st Support Level 82.16
2nd Support Level 79.31
3rd Support Level 77.13

See More

52-Week High 148.15
Fibonacci 61.8% 122.69
Fibonacci 50% 114.82
Fibonacci 38.2% 106.96
Last Price 87.38
52-Week Low 81.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar